Beijing’s EdiGene raised $11 million in a Series pre-B2 financing to develop novel therapeutics based on gene editing following earlier $15 million and $10 million pre-B financings. In addition, EdiGene announced a research collaboration with a clinical stage biopharma that is developing novel off-the-shelf T-cell therapies for cancer. No further details of the partnership were disclosed. Participants in the latest funding are Series A lead investor IDG Capital and Series pre-B lead investor Lilly Asia Ventures. Source: China Biotoday
